VANSEN PHARMA INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-03-27: Form 8-K; Period of report 2014-11-14; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-03-18: Form 8-K; Period of report 2014-03-10; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; Details 1.01.
- 2014-03-03: Form 8-K; Period of report 2014-02-24; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2014-01-21: Form 8-K; Period of report 2014-01-21; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.06 Change in Shell Company Status; Details 2.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-03-27 | 8-K | 2014-11-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 14, 2014, our board of directors received and accepted the resignation of Moira Ong as our chief financial officer, secretary and treasurer. | vnsn_8k.htm |
| 2014-03-18 | 8-K | 2014-03-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 On March 10, 2013, we entered into a purchase and sale agreement between our company, 6708595 Canada Inc., a Canada corporation and Kazem Agharazi. 3.02 Effective March 13, 2014, we issued 110,000 shares of common stock in connection with the purchase and sale agreement to one non U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. 7.01 On March 17, 2014, we issued a news release with respect to the purchase and sale agreement. | vnsn_8k.htm |
| 2014-03-03 | 8-K | 2014-02-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective February 24, 2014, Richard Azani resigned as a director and officer of our company. 7.01 On March 3, 2014, we issued a news release announcing a change to our directors and officers. | vnsn_8k.htm |
| 2014-01-21 | 8-K | 2014-01-21 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.06 Change in Shell Company Status | 2.01 (f) of Form 8-K states that if the registrant was a shell company, as we were immediately before the acquisition of assets under Item 2.01, then the registrant must disclose the information that would be required if the registrant were filing a general form for registration of securities on Form 10. 5.06 Our management has determined that, as of the closing of the acquisitions above, our company has ceased to be a shell company as defined in Rule 12b-2 of the United States Securities Exchange Act of 1934, as amended. | vnsn_8k.htm |
| 2013-11-29 | 8-K/A | 2013-07-30 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On July 30, 2013, we entered into and closed an asset purchase agreement between our company and Vansen Pharma, Inc. Pursuant to the agreement we have agreed to purchase the right, title and interest to certain Spectracef® and cefditoren pivoxil products in the United States, along with related contracts, records, inventories and product registrations. 3.02 Effective July 30, 2013, we issued 3,625,000 shares of common stock to Vansen, a non U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. 5.02 Effective July 30, 2013, Maria Peralta resigned as a director and officer of our company and Richard Azani and Patrick Charles Frankham were appointed directors of our company. 8.01 On July 30, 2013, our board of directors approved the change of our name to “Vansen Pharma Inc.”. | vnsn_8ka.htm |
| 2013-10-28 | 8-K | 2013-10-10 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (i) On October 10, 2013, our company formally informed Malone Bailey LLP, Certified Public Accounting Firm of their dismissal as our company’s independent registered public accounting firm. | vnsn_8k.htm |
| 2013-08-30 | 8-K | 2013-08-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On August 7, 2013, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary Vansen Pharma Inc., a Nevada corporation, to effect a name change from Okana Ventures, Inc. to Vansen Pharma Inc. Vansen Pharma Inc. was formed solely for the change of name. | oknv_8k.htm |
| 2013-08-08 | 8-K | 2013-07-30 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On July 30, 2013, we entered into and closed an asset purchase agreement between our company and Vansen Pharma, Inc. Pursuant to the agreement we have agreed to purchase the right, title and interest to certain Spectracef® and cefditoren pivoxil products in the United States, along with related contracts, records, inventories and product registrations. 3.02 Effective July 30, 2013, we issued 3,625,000 shares of common stock to Vansen, a non U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. 5.02 Effective July 30, 2013, Maria Peralta resigned as a director and officer of our company and Richard Azani and Patrick Charles Frankham were appointed directors of our company. 8.01 On July 30, 2013, our board of directors approved the change of our name to “Vansen Pharma Inc.”. | okana_8k.htm |
| 2013-02-22 | 8-K | 2013-02-21 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On February 21, 2013, Anderson Bradshaw PLLC of Salt Lack City, Utah (“Anderson Bradshaw”) was dismissed by Okana Ventures, Inc. (the Company”) as independent registered public accounting firm. | okana_8k.htm |
| 2012-08-20 | 8-K | 2012-08-01 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On or about August 1, 2012, Child, Van Wagoner & Bradshaw, PLLC (“CVB”), the principal accountant for Okana Ventures, Inc. (the "Company") ceased its accounting practice for SEC reporting companies. | oknv_8k.htm |
| 2011-03-31 | 8-K | 2011-03-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 30, 2011, Okana Ventures Inc., (“we”, “us”, “our”) received a resignation from Michael Upham as our President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and director. | form8k.htm |
| 2010-08-12 | 8-K | 2010-08-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 9, 2010, the Company entered into an agreement with Beeston Enterprises Ltd. ("Beeston") under which Beeston granted the Company an option to purchase a certain mineral property, comprising approximately 478 hectares, located in the Clinton Mining District of British Columbia, Canada (the "Property"). | okanaform8kbeestonoptionagre.htm |
| 2009-07-07 | 8-K | 2009-07-01 | 8.01 Other Events | 8.01 Effective July 1, 2009, the Company retained the services of Pacific Stock Transfer Company, of Suite 240 – 500 East Warm Springs Road, Las Vegas, Nevada 89119, as the stock transfer agent and registrar of its common stock. | okanaform8kjuly12009changeof.htm |
| 2008-08-25 | 8-K | 2008-08-11 | 8.01 Other Events | okana8kaddresschange.htm | |
| 2008-07-14 | 8-K | 2008-07-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | okanaform8kreuphamappointmen.htm | |
| 2008-07-01 | 8-K | 2008-06-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | okanaform8krebirchresignatio.htm | |
| 2008-04-24 | 8-K | 2008-04-18 | 1.02 Termination of a Material Definitive Agreement | okanaform8kreagreementtermin.htm | |
| 2008-04-01 | 8-K | 2008-03-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | okanaform8kreweissresignatio.htm | |
| 2007-06-22 | 8-K | 2007-06-18 | 8.01 Other Events | offering8k_0607.htm | |
| 2007-05-07 | 8-K | 2007-05-07 | 8.01 Other Events | extension8k.htm |